Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
polymyositis market insight

SALE

Polymyositis- Market Insight, Epidemiology and Market Forecast -2030

Published Date : 2021

Pages : 126

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
Companies
- Sample Request

polymyositis market insight

DelveInsight’s ‘Polymyositis—Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Polymyositis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Polymyositis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Polymyositis market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current Polymyositis treatment practice/algorithm and unmet medical needs to curate the best opportunities and assess the underlying market potential.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2018–2030

Polymyositis Disease Understanding and Treatment Algorithm

The DelveInsight’s Polymyositis market report gives a thorough understanding of the Polymyositis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Polymyositis Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Polymyositis.

Polymyositis Treatment

It covers the details of conventional and current medical therapies available in the Polymyositis market for the treatment of the condition. It also provides Polymyositis treatment algorithms and guidelines in the United States, Europe, and Japan.

Polymyositis Epidemiology

The Polymyositis epidemiology section provides insights about the historical and current Polymyositis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Polymyositis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Polymyositis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2018–2030.

Country Wise- Polymyositis Epidemiology

The epidemiology segment also provides the Polymyositis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Polymyositis Drug Chapters

The drug chapter segment of the Polymyositis report encloses the detailed analysis of Polymyositis marketed drugs and late-stage (Phase-III and Phase-II) Polymyositis pipeline drugs. It also helps to understand the Polymyositis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Polymyositis Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Polymyositis treatment.

Polymyositis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Polymyositis treatment.

Polymyositis Market Outlook

The Polymyositis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Polymyositis market trends by analyzing the impact of current Polymyositis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Polymyositis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Polymyositis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Polymyositis market in 7MM is expected to witness a major change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Polymyositis market in 7MM.

The United States Market Outlook

This section provides the total Polymyositis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Polymyositis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Polymyositis market size and market size by therapies in Japan is also mentioned.

Polymyositis Drugs Uptake

This section focuses on the rate of uptake of the potential Polymyositis drugs recently launched in the Polymyositis market or expected to get launched in the market during the study period 2018–2030. The analysis covers Polymyositis market uptake by drugs; patient uptake by therapies; and sales of each drug.

Polymyositis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Polymyositis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Polymyositis Pipeline Development Activities

The Polymyositis report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Polymyositis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Polymyositis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Polymyositis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Polymyositis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Polymyositis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Polymyositis market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of Polymyositis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
Comprehensive insight has been provided into the Polymyositis epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Polymyositis is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
A detailed review of the Polymyositis market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies by understanding trends shaping and driving the global Polymyositis market.

Report Highlights

In the coming years, the Polymyositis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Polymyositis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for Polymyositis. The launch of emerging therapies will significantly impact the Polymyositis market.
A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Polymyositis.
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Polymyositis Report Insights

Patient Population
Therapeutic Approaches
Polymyositis Pipeline Analysis
Polymyositis Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Polymyositis Report Key Strengths

10-years Forecast
7MM Coverage
Polymyositis Epidemiology Segmentation
Key Competitors
Highly Analyzed Market
Drugs Uptake

Polymyositis Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness

Key Questions

Market Insights:

What was the Polymyositis Market share (%) distribution in 2018, and how would it look in 2030?
What would be the Polymyositis total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
What are the key findings pertaining to the market across 7MM, and which country will have the largest Polymyositis market Size during the forecast period (2018–2030)?
At what CAGR is the Polymyositis market expected to grow in the 7MM forecast period (2018–2030)?
What would be the Polymyositis market outlook across the 7MM during the forecast period (2018–2030)?
What would be the Polymyositis market growth till 2030, and what will be the resultant market Size in the year 2030?

Epidemiology Insights:

What are the disease risk, burden, and unmet needs of Polymyositis?
What is the historical Polymyositis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Polymyositis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM concerning the patient population pertaining to Polymyositis?
Out of all 7MM countries, which country would have the highest prevalence of Polymyositis during the forecast period (2018–2030)?
At what CAGR is the population expected to grow in the 7MM forecast period (2018–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the treatment of Polymyositis?
What are the current treatment guidelines for treating Polymyositis in the USA, Europe, and Japan?
What are the Polymyositis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
How many companies are developing therapies for the treatment of Polymyositis?
How many therapies are developed by each company for the treatment of Polymyositis?
How many emerging therapies are in the mid-stage and late stages of development for the treatment of Polymyositis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polymyositis therapies?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Polymyositis and its status?
What have key designations been granted for the emerging therapies for Polymyositis?
What are the global historical and forecasted markets for Polymyositis?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Polymyositis market
Organize sales and marketing efforts by identifying the best opportunities for Polymyositis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for the Polymyositis market.
To understand the future market competition in the Polymyositis market.

1. Key Insights

2. Report Introduction

3. Polymyositis Market Overview at a Glance

3.1. Market Share (%) of Polymyositis by Therapies in 2018

3.2. Market Share (%) of Polymyositis by Therapies in 2030

4. Executive Summary of Polymyositis

5. Polymyositis: Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Etiology

5.4. Pathophysiology

5.5. Diagnosis

6. Differential Diagnosis

6.1. Treatment

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalence of Polymyositis

7.3. Epidemiology of Polymyositis

7.4. The United States

7.4.1. Prevalence of Polymyositis in the United States

7.4.2. Gender-specific cases of Polymyositis in the United States

7.4.3. Age-specific cases of Polymyositis in the United States

7.5. EU5

7.5.1. Total Prevalence of Polymyositis in EU5

7.5.2. Germany

7.5.2.1. Gender-specific cases of Polymyositis in Germany

7.5.2.2. Age-specific cases of Polymyositis in Germany

7.5.3. France

7.5.3.1. Gender-specific cases of Polymyositis in France

7.5.3.2. Age-specific cases of Polymyositis in France

7.5.4. Italy

7.5.4.1. Gender-specific cases of Polymyositis in Italy

7.5.4.2. Age-specific cases of Polymyositis in Italy

7.5.5. Spain

7.5.5.1. Gender-specific cases of Polymyositis in Spain

7.5.5.2. Age-specific cases of Polymyositis in Spain

7.5.6. The United Kingdom

7.5.6.1. Gender-specific cases of Polymyositis in the United Kingdom

7.5.6.2. Age-specific cases of Polymyositis in the United Kingdom

7.6. Japan

7.6.1. Prevalence of Polymyositis in Japan

7.6.2. Gender-specific cases of Polymyositis in Japan

7.6.3. Age-specific cases of Polymyositis in Japan

8. Patient Journey

9. Marketed Therapy

9.1. Acthar Gel (corticotropin): Boehringer Ingelheim Pharmaceuticals

9.1.1. Product Description

9.1.2. Safety and Efficacy

9.1.3. Side Effects

9.1.4. Product Profile

9.2. Venoglobulin: Mitsubishi Tanabe Pharma

9.2.1. Product Description

9.2.2. Regulatory Milestones

9.2.3. Product Profile

10. Emerging Therapies

10.1. Key Cross Competition

10.2. Stelara (Ustekinumab): Janssen Pharmaceutical KK.

10.2.1. Product Description

10.2.2. Clinical Development

10.2.3. Clinical trials information

10.2.4. Product Profile

10.2.5. Analysts’ Views

10.3. KZR-616: Kezar Life Sciences

10.3.1. Product Description

10.3.2. Other Development Activities

10.3.3. Clinical Development

10.3.4. Clinical trials information

10.3.5. Product Profile

10.3.6. Analysts’ Views

11. Other Assets

11.1. Key Competitors: Other Assets

11.2. Orencia (Abatacept): Bristol-Myers Squibb/ ONO Pharma

11.2.1. Product Description

11.2.2. Other Development Activities

11.2.3. Clinical Development

11.2.4. Clinical trials information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Daxdilimab (HZN-7734/MEDI7734/ VIB7734): Horizon Therapeutics

11.3.1. Product Description

11.3.2. Other Development Activities

11.3.3. Clinical Development

11.3.4. Clinical trials information

11.3.5. Product Profile

11.4. PF1801: Immunoforge

11.4.1. Product Description

11.4.2. Other Development Activity

11.4.3. Product Profile

11.5. Umbilical Cord Lining Stem Cells: Restem, LLC.

11.5.1. Product Description

11.5.2. Clinical Development

11.5.3. Clinical Trials Information

11.5.4. Product Profile

11.6. Olumiant (Baricitinib): Eli Lilly and Company

11.6.1. Product Description

11.6.2. Clinical Development

11.6.3. Clinical trials information

11.6.4. Product Profile

12. Polymytosis: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Size of Polymyositis in 7MM

12.3. Market Outlook

12.4. The United States Market Size

12.4.1. Total Market Size of Polymyositis in the United States

12.4.2. Market Size of Polymyositis by Therapies in the United States

12.5. Market Size of Polymyositis in EU-5

12.5.1. Market Size of Polymyositis by Therapies in Germany

12.5.2. Market Size of Polymyositis by Therapies in France

12.5.3. Market Size of Polymyositis by Therapies in Italy

12.5.4. Market Size of Polymyositis by Therapies in Spain

12.5.5. Market Size of Polymyositis by Therapies in the United Kingdom

12.6. Japan Market Size

12.6.1. Total Market Size of Polymyositis in Japan

12.6.2. Market Size of Polymyositis by Therapies in Japan

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access

17. Appendix

17.1. Report Methodology

17.2. Bibliography

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables:

List of Table

Table 1: Summary of Polymyositis, Epidemiology, and Key Events (2018–2030)

Table 2: Bohan and Peter criteria for Polymyositis

Table 3: Autoantibodies in PM

Table 4: Therapeutic regimens for PM

Table 5: Prevalence of Polymyositis in the 7MM (2018–2030)

Table 6: Prevalence of Polymyositis in the United States (2018–2030)

Table 7: Gender-specific cases of Polymyositis in the United States (2018–2030)

Table 8: Age-specific cases of Polymyositis in the United States (2018–2030)

Table 9: Prevalence of Polymyositis in EU5 (2018–2030)

Table 10: Gender-specific cases of Polymyositis in Germany (2018–2030)

Table 11: Age-specific cases of Polymyositis in Germany (2018–2030)

Table 12: Gender-specific cases of Polymyositis in France (2018–2030)

Table 13: Age-specific cases of Polymyositis in France (2018–2030)

Table 14: Gender-specific cases of Polymyositis in Italy (2018–2030)

Table 15: Age-specific cases of Polymyositis in Italy (2018–2030)

Table 16: Gender-specific cases of Polymyositis in Spain (2018–2030)

Table 17: Age-specific cases of Polymyositis in Spain (2018–2030)

Table 18: Gender-specific cases of Polymyositis in the United Kingdom (2018–2030)

Table 19: Age-specific cases of Polymyositis in the United Kingdom (2018–2030)

Table 20: Prevalence of Polymyositis in Japan (2018–2030)

Table 21: Gender-specific cases of Polymyositis in Japan (2018–2030)

Table 22: Age-specific cases of Polymyositis in Japan (2018–2030)

Table 23: Key Competitors: Emerging Therapies

Table 24: Stelara (ustekinumab), Clinical Trial Description, 2021

Table 25: KZR-616, Clinical Trial Description, 2021

Table 26: Orencia (Abatacept), Clinical Trial Description, 2021

Table 28: Daxdilimab (HZN-7734), Clinical Trial Description, 2021

Table 29: Umbilical Cord Lining Stem Cells, Clinical Trial Description, 2021

Table 30: Olumiant (Baricitinib), Clinical Trial Description, 2021

Table 31: Seven Major Market Size of Polymyositis in USD Million (2018–2030)

Table 32: Market Size of Polymyositis in the United States in USD Million (2018–2030)

Table 33: The US Market Size of Polymyositis by Therapies in USD Million (2018–2030)

Table 34: EU5 Market Size of Polymyositis in USD Million (2018–2030)

Table 35: Market Size of Polymyositis by Therapies in Germany in USD Million (2018–2030)

Table 36: Market Size of Polymyositis by Therapies in France in USD Million (2018–2030)

Table 37: Market Size of Polymyositis by Therapies in Italy in USD Million (2018–2030)

Table 38: Market Size of Polymyositis by Therapies in Spain in USD Million (2018–2030)

Table 39: Market Size of Polymyositis by Therapies in the United Kingdom in USD Million (2018–2030)

Table 40: Market Size of Polymyositis in Japan in USD Million (2018–2030)

Table 41: Market Size of Polymyositis by Therapies in Japan in USD Million (2018–2030)

List of Figures:

List of Figures

Figure 1: Pathways involved in the pathophysiology of PM

Figure 2: Potential immune mechanisms in myositis pathogenesis

Figure 3: Immune-related potential therapeutic targets in myositis

Figure 4: Diagnostic Tests for PM

Figure 5: Diagnostic Algorithm for PM

Figure 6: Overview of treatment essentials in PM

Figure 7: Total Prevalent Population of Polymyositis in 7MM (2018–2030)

Figure 8: Prevalence of Polymyositis in the United States (2018–2030)

Figure 9: Gender-specific cases of Polymyositis in the United States (2018–2030)

Figure 10: Age-specific cases of Polymyositis in the United States (2018–2030)

Figure 11: Total Prevalent Population of Polymyositis in EU5 (2018–2030)

Figure 12: Gender-specific cases of Polymyositis in Germany (2018–2030)

Figure 13: Age-specific cases of Polymyositis in Germany (2018–2030)

Figure 14: Gender-specific cases of Polymyositis in France (2018–2030)

Figure 15: Age-specific cases of Polymyositis in France (2018–2030)

Figure 16: Gender-specific cases of Polymyositis in Italy (2018–2030)

Figure 17: Age-specific cases of Polymyositis in Italy (2018–2030)

Figure 18: Gender-specific cases of Polymyositis in Spain (2018–2030)

Figure 19: Age-specific cases of Polymyositis in Spain (2018–2030)

Figure 20: Gender-specific cases of Polymyositis in the United Kingdom (2018–2030)

Figure 21: Age-specific cases of Polymyositis in the United Kingdom (2018–2030)

Figure 22: Prevalence of Polymyositis in Japan (2018–2030)

Figure 23: Gender-specific cases of Polymyositis in Japan (2018–2030)

Figure 24: Age-specific cases of Polymyositis in Japan (2018–2030)

Figure 25: Seven Major Market Size of Polymyositis in USD Million (2018–2030)

Figure 26: Market Size of Polymyositis in the United States in USD Million (2018–2030)

Figure 27: Market Size of Polymyositis in the United States by Therapies (2018–2030)

Figure 28: EU5 Market Size of Polymyositis in USD Million (2018–2030)

Figure 29: Market Size of Polymyositis in Germany by Therapies (2018–2030)

Figure 30: Market Size of Polymyositis in France by Therapies (2018–2030)

Figure 31: Market Size of Polymyositis in Italy by Therapies (2018–2030)

Figure 32: Market Size of Polymyositis in Spain by Therapies (2018–2030)

Figure 33: Market Size of Polymyositis in the United Kingdom by Therapies (2018–2030)

Figure 34: Market Size of Polymyositis in Japan in USD Million (2018–2030)

Figure 35: Market Size of Polymyositis in Japan by Therapies (2018–2030)

Tags:

License Type

Offer